Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

ALSGX vs. SBIO: which is better?

Bottom line

ALSGX vs SBIO: the short answer

ALSGX (ALPS/Stadion Tactical Growth Portfolio) and SBIO (ALPS Medical Breakthroughs ETF) are both mutual funds.

Updated Nov 19, 2026

ALSGX vs SBIO side by side

ALSGXSBIO
TypeMutual fundETF
Fund familyAlps VariableAlps
CategoryLarge GrowthHealth Care Sector
Expense ratio—0.5%
Annual cost per $10k—$50
10-yr cost on $10k (prospectus)—$628
Max front load—None
12b-1 fee——
1-yr return—+54.2%
5-yr return (annualized)—+0.7%
10-yr return (annualized)—+5.7%
Best quarter—+33.9%
Worst quarter—−30.8%
Net assets (fund)—$161.8M
Number of holdings—89
Portfolio turnover—58%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

ALSGX and SBIO share none of their top holdings.

ALSGX top 10

    SBIO top 10

    1. Alkermes Plc — 4.48%
    2. Kymera Therapeutics Inc — 4.23%
    3. Celcuity Inc — 3.92%
    4. Mirum Pharmaceuticals Inc — 3.90%
    5. Spyre Therapeutics Inc — 3.68%
    6. Cg Oncology Inc — 3.35%
    7. Apogee Therapeutics Inc — 2.93%
    8. Xenon Pharmaceuticals Inc — 2.90%
    9. Travere Therapeutics Inc — 2.77%
    10. Dianthus Therapeutics Inc — 2.64%

    FAQ

    What is the difference between ALSGX and SBIO?
    ALSGX (ALPS/Stadion Tactical Growth Portfolio) and SBIO (ALPS Medical Breakthroughs ETF) are both mutual funds.
    Should I own both ALSGX and SBIO?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.